Fig. 5
From: Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
Immunoregulatory therapies for MASLD. Although most pharmacological strategies primarily target metabolic processes, aiming at ameliorating metabolic dysfunction-driven stress and injury in hepatocytes, these potential “MASH therapies” also inhibit the immune cell-mediated inflammatory response
